Book a meeting
DO-BO

How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?

Tune in to the new episode of the Market Access Podcast (MAP), where Dr. Stefan Walzer, a pioneer in Market Access 4.0, explores groundbreaking solutions and innovative technologies shaping the future of healthcare reimbursement. Discover how AI-based platforms like Q-Bo and Wafle are revolutionizing health care trainings with all stakeholders.

Special guest Rodrigo Silva shares his insights on the transformative power of virtual reality in healthcare, from enhancing nurse training to potential applications in the pharmaceutical industry. Discover how these technologies are revolutionizing market access and how digital health platforms can address critical healthcare challenges like nursing shortages.

Related

Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour?

By

Stefan Walzer

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

What lessons can Market Access teams learn from an Olympic medalist, Livia Altmann?

By

Stefan Walzer

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]